PMID- 25550575
OWN - NLM
STAT- MEDLINE
DCOM- 20150310
LR  - 20220321
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 35
IP  - 1
DP  - 2015 Jan
TI  - Differential impact of fosaprepitant on infusion site adverse events between 
      cisplatin- and anthracycline-based chemotherapy regimens.
PG  - 379-83
AB  - BACKGROUND: Fosaprepitant may be associated with infusion site adverse events 
      (AEs), and these adverse events possibly vary according to chemotherapy regimen. 
      PATIENTS AND METHODS: 267 oncology patients who were administered anthracycline- 
      or cisplatin-based regimens were retrospectively studied. Multivariate logistic 
      regression was performed in stratified analyses to evaluate potential 
      regimen-specific effects of fosaprepitant. RESULTS: 41.7% of patients 
      administered fosaprepitant experienced infusion site AEs. On the other hand, only 
      10.9% of patients administered aprepitant experienced AEs. Multivariate analysis 
      showed a statistically significant overall increased risk of infusion site 
      reaction associated with fosaprepitant (p<0.001), but when evaluated separately 
      according to chemotherapy regimen, this relationship appeared to be largely 
      confined to patients receiving an anthracycline-based regimen (OR=12.95, 
      95%CI=5.74-29.20). No association was observed among patients on cisplatin-based 
      regimens. A test for interaction was statistically significant (p=0.001). 
      CONCLUSION: Fosaprepitant is associated with an elevated risk of infusion site 
      reaction in patients receiving anthracyclines.
CI  - Copyright(c) 2015 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Fujii, Takeo
AU  - Fujii T
AD  - Division of Medical Oncology, Department of Internal Medicine, St. Luke's 
      International Hospital, Tokyo, Japan Division of Pulmonary Medicine, Department 
      of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan.
FAU - Nishimura, Naoki
AU  - Nishimura N
AD  - Division of Pulmonary Medicine, Department of Internal Medicine, St. Luke's 
      International Hospital, Tokyo, Japan nina@luke.ac.jp.
FAU - Urayama, Kevin Y
AU  - Urayama KY
AD  - Department of Human Genetics and Disease Diversity, Tokyo Medical and Dental 
      University, Tokyo, Japan Center for Clinical Epidemiology, St. Luke's Life 
      Science Institute, Tokyo, Japan.
FAU - Kanai, Hisako
AU  - Kanai H
AD  - Breast Center/Oncology Center, St. Luke's International Hospital, Tokyo, Japan.
FAU - Ishimaru, Hiromasa
AU  - Ishimaru H
AD  - Department of Pharmacology, St. Luke's International Hospital, Tokyo, Japan.
FAU - Kawano, Junko
AU  - Kawano J
AD  - Department of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan.
FAU - Takahashi, Osamu
AU  - Takahashi O
AD  - Center for Clinical Epidemiology, St. Luke's Life Science Institute, Tokyo, 
      Japan.
FAU - Yamauchi, Hideko
AU  - Yamauchi H
AD  - Department of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan.
FAU - Yamauchi, Teruo
AU  - Yamauchi T
AD  - Division of Medical Oncology, Department of Internal Medicine, St. Luke's 
      International Hospital, Tokyo, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Anthracyclines)
RN  - 0 (Antiemetics)
RN  - 0 (Morpholines)
RN  - 6L8OF9XRDC (fosaprepitant)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anthracyclines/administration & dosage
MH  - Antiemetics/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use
MH  - Breast Neoplasms/drug therapy
MH  - Cisplatin/administration & dosage
MH  - Female
MH  - Humans
MH  - Infusions, Parenteral
MH  - Lung Neoplasms/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Morpholines/*therapeutic use
MH  - Nausea/chemically induced/*drug therapy
MH  - Retrospective Studies
MH  - Skin Diseases/*chemically induced
OTO - NOTNLM
OT  - Fosaprepitant
OT  - anthracycline
OT  - cisplatin
OT  - infusion site adverse events
EDAT- 2015/01/01 06:00
MHDA- 2015/03/11 06:00
CRDT- 2015/01/01 06:00
PHST- 2015/01/01 06:00 [entrez]
PHST- 2015/01/01 06:00 [pubmed]
PHST- 2015/03/11 06:00 [medline]
AID - 35/1/379 [pii]
PST - ppublish
SO  - Anticancer Res. 2015 Jan;35(1):379-83.